Podcast #206 · 17 Dec 2024
Biochemical Recurrence: Insights from AUA/ASTRO/SUO Guidelines
- Prostate Cancer
- Prostate-Specific Membrane Antigen PET (PSMA PET)
- Androgen Deprivation Therapy (ADT)
- Urologic Oncology
- Genomic Testing
- Radiation Therapy
- Biochemical Recurrence (BCR)
Have you checked out the AUA/ASTRO/SUO’s recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management.
This podcast is supported by
Timestamps
Resources
More about this episode
The doctors focus on the difficulty in declaring a patient 'cured' and the implications of biochemical recurrence after treatment. Dr. Morgan highlights the importance of PSA in the postoperative setting and explores the role of the Decipher Prostate Genomic Classifier in personalizing treatment. He talks through the latest AUA/ASTRO/SUO consensus on biochemical recurrence guidelines, including the significance of early salvage therapy and the integration of advanced imaging techniques like PSMA PET scans. Further, Dr. Morgan emphasizes the role for multidisciplinary evaluation, patient counseling, and future directions of research to refine treatment options. This discussion underscores the transition from adjuvant to early salvage radiation as a standard practice and considers emerging biomarker strategies to inform treatment decisions.